ReviewBiomolecules2021
Lipoprotein(a)-The Crossroads of Atherosclerosis, Atherothrombosis and Inflammation.
Review in Biomolecules, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- Impact of elevated lipoprotein(a) levels on the functional outcomes of ischemic stroke patients: A systematic review and meta-analysis.European journal of neurology · 2024Pooled it
- A Systematic Review on the Risk Modulators of Myocardial Infarction in the "Young"-Implications of Lipoprotein (a).International journal of molecular sciences · 2023Pooled it
- Lipoprotein (a) Levels and Abdominal Aortic Aneurysm. A Systematic Review and Meta-analysis.Current pharmaceutical design · 2022Pooled it
- Proprotein convertase subtilisin/kexin type 9-CC-motif chemokine ligand 2 interactions link lipoprotein(a) composition to intermediate monocyte inflammation in coronary artery disease.Atherosclerosis plus · 2026Article
- Lipoprotein(a) -Related Cognitive Vulnerability After Stroke Beyond High-Sensitivity C-Reactive Protein.Translational stroke research · 2026Article
- Lp(a) Has Specific Effects on Coronary Artery Disease Independent of LDL-C: A Mendelian Randomization Study.JACC. Advances · 2026Article
- Residual risk in atherosclerotic cardiovascular disease after statin therapy: Clinical mechanisms and management strategies.World journal of cardiology · 2026Review
- Lipoprotein(a) Levels and Adverse Outcomes in Heart Failure.Journal of cardiac failure · 2026Article
- PCSK9 Inhibitors Increase CD34+ But Not Other Endothelial Progenitor Cells in Patients with Chronic Coronary Disease and Increased Lp(a) Values.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Clinical utility of lipoprotein(a) and the ApoB/ApoA-I ratio in the risk assessment of acute coronary syndrome: from single biomarkers to integrated risk stratification.Frontiers in cardiovascular medicine · 2026Review
- Systemic inflammation modulates lipoprotein(a)-associated coronary stenosis in the chronic coronary syndromes.American journal of preventive cardiology · 2025Article
- Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage.International journal of molecular sciences · 2025Review
- Genetic and epigenetic architectures of stroke: Insights from GWAS to precision medicine.Neurochemistry international · 2025Review
- Cardiovascular Implications of Lipoprotein(a) and its Genetic Variants: A Critical Review From the Middle East.JACC. Asia · 2025Review
- Clinical characteristics and risk factors of cardiovascular disease in systemic lupus erythematosus patients.Heart and vessels · 2025Article
- Commentary on: Lipoprotein(a), remote ischemic conditioning, and stroke recurrence in patients with symptomatic intracranial atherosclerotic stenosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025Review
- Lipoprotein(a): Assessing the Current Knowledge and Gaps in Screening and Treatment-A Narrative Review.Journal of cardiovascular development and disease · 2025Review
- Association between lipoprotein(a) and diabetic peripheral neuropathy in patients with type 2 diabetes: a meta-analysis.Diabetology & metabolic syndrome · 2025Article
- The Association between Lipoprotein(a) and Coronary Artery Calcification in Elderly Patients with Diabetes: A Cross-Sectional Study.Reviews in cardiovascular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased lipoprotein(a) (Lp(a)) levels are an independent predictor of coronary artery disease (CAD), degenerative aortic stenosis (DAS), and heart failure independent of CAD and DAS. Lp(a) levels are genetically determinated in an autosomal dominant mode, with great intra- and inter-ethnic diversity. Most variations in Lp(a) levels arise from genetic variations of the gene that encodes the apolipoprotein(a) component of Lp(a), the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.